Intelligence Platform

Patents

Browse 22 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed

patent

US 12419870

Compositions and methods for immune cell modulation in adoptive immunotherapies

Fate Therapeutics, Inc. · Granted Tue Sep 23 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 18 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12415843

Antibody-interferon fusion proteins for enhancing adoptive T cell therapies for the treatm

The Regents of the University of California · Granted Tue Sep 16 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 11 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12397028

Adoptive cellular therapy

REGENERON PHARMACEUTICALS, INC. · Granted Tue Aug 26 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 21 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12295971

Compositions and methods for enhancing adoptive T cell therapeutics

The Regents of the University of California · Granted Tue May 13 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 08 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12281329

Compositions and methods for immune cell modulation in adoptive immunotherapies

Fate Therapeutics, Inc. · Granted Tue Apr 22 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 17 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12121540

CBL inhibitors and compositions for use in adoptive cell therapy

NURIX THERAPEUTICS, INC. · Granted Tue Oct 22 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 17 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12036241

Compositions and methods for immune cell modulation in adoptive immunotherapies

Fate Therapeutics, Inc. · Granted Tue Jul 16 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 11 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12036256

Adoptive cellular therapy

REGENERON PHARMACEUTICALS, INC. · Granted Tue Jul 16 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 11 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11932870

Compositions and methods for immune cell modulation in adoptive immunotherapies

Fate Therapeutics, Inc. · Granted Tue Mar 19 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 14 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11925663

Methods of managing tumor flare in adoptive immunotherapy

Atara Biotherapeutics, Inc. · Granted Tue Mar 12 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 07 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11433131

Adoptive cell therapy using spherical nucleic acids (SNAs)

Northwestern University · Granted Tue Sep 06 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 01 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11413309

Compositions and methods for immune cell modulation in adoptive immunotherapies

Fate Therapeutics, Inc. · Granted Tue Aug 16 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 11 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11401506

Enhanced expansion of tumor-infiltrating lymphocytes for adoptive cell therapy

Board nf Regents The Inivercitvof Texas Cvctom · Granted Tue Aug 02 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 28 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11318164

Immunotherapeutic treatment method using an interleukin-2 receptor beta-selective agonist

Nektar Therapeutics · Granted Tue May 03 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 28 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11096964

Compositions and methods for immune cell modulation in adoptive immunotherapies

Fate Therapeutics, Inc. · Granted Tue Aug 24 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 19 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9675633

miRNA for treating cancer and for use with adoptive immunotherapies

The Board of Regents of the University of Texas System · Granted Tue Jun 13 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 08 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9512401

B and T lymphocyte attenuator marker for use in adoptive T-cell therapy

The Board of Regents of the University of Texas System · Granted Tue Dec 06 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 01 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9074185

Adoptive cell therapy with young T cells

The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Jul 07 2015 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 02 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8883500

Method of preparing adenosine-resistant anti-tumor T lymphocytes for adoptive immunotherap

Northwestern University · Granted Tue Nov 11 2014 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 06 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8541185

Method of predicting responsiveness to autologous adoptive cell transfer therapy

TEL HASHOMER MEDICAL RESEARCH INFRASTRUCTURE AND SERVICES LTD. · Granted Tue Sep 24 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 19 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8383099

Adoptive cell therapy with young T cells

The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Feb 26 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 21 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 7998736

Adoptive immunotherapy with enhanced T lymphocyte survival

The United States of America, as represented by the Department of Health and Human Services · Granted Tue Aug 16 2011 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 11 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

granted